Coeptis Therapeutics Holdings, Inc. announced on February 11, 2026, a repricing/exchange program for options held by executives, allowing a switch to restricted stock, and confirmed regaining compliance with Nasdaq listing rules on February 9, 2026. This program involved top officers surrendering notable amounts of options for restricted stock equivalencies.